激素受体阳性乳腺癌靶向治疗的研究进展

Research Advances in Targeted Therapies for Luminal Breast Cancer

乳腺癌是女性发病率最高的癌症,激素受体阳性乳腺癌因其拥有针对性的医治成为乳腺癌临床研究的关注点,分子靶向治疗已成为乳腺癌治疗的新风向,靶向药物联合内分泌治疗已经改变了激素受体阳性乳腺癌临床实践,本篇文章将在激素受体阳性乳腺癌的临床病理特征的基础之上,对其常见的靶点、信号通路,如:细胞周期蛋白依赖性激酶4和6 (Cyclin-dependent kinases 4 and 6, CDK4/6)、脂酰肌醇3⁃激酶(PI3K)/蛋白激酶B (AKT)/哺乳动物雷帕霉素靶蛋白(mTOR)信号通路(Lipodylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target rapamycin (mTOR)),即PAM信号通路、组蛋白去乙酰化酶(histone deacetylase, HDAC)及其对应的靶向药物的最新研究进展做概述。

Breast cancer is the highest incidence of cancer in women, luminal breast cancer because of its tar-geted treatment has become a hot spot in clinical research of breast cancer, molecular targeted therapy has become a new trend in breast cancer treatment, targeted drugs combined with endo-crine therapy has changed the clinical practice of lumen breast cancer, this article will be on the ba-sis of the clinicopathological characteristics of cavity-faced breast cancer, on the basis of its common targets, signaling pathways, such as cyclin-dependent kinases 4 and 6 (CDK4/6), PAM signaling pathway, recent research advances in histone deacetylase (HDAC) and its corresponding targeted drugs are outlined.